The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year ...

An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib ...

Discover a study that also highlighted that treatment intensification with enzalutamide benefited patients regardless of ...

Adding enzalutamide (Xtandi) to androgen deprivation therapy (ADT) can extend metastasis-free survival while maintaining quality of life in men with prostate cancer who have a high risk for ...

The blocker, enzalutamide, improved outcomes in a range of prostate cancers even where chemotherapy is ineffective. Enzalutamide works by reducing the ability of prostate cancer cells to bind to ...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, ...

Five- and eight-year trial data to be presented at ASCO demonstrate durable survival outcomes with Xtandi (enzalutamide) plus ...

The new therapy combines two existing cancer drugs, enzalutamide and talazoparib. Enzalutamide, known by its brand name XTANDI, has been used as a treatment for metastatic castration-resistant ...

Ed Burgess, diagnosed with stage IV prostate cancer, shares his journey of survival thanks to a combination of hormone therapy and the drug enzalutamide, highlighting the personal impact of research ...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months ...